The UK metformin in Li Fraumeni (MILI) Study

Sarah Blagden

Funded by NIHR & CRUK

The UK's MILI team



Chief Investigator

Prof Sarah Blagden Medical Oncologist, University of Oxford.



Translational Leads

Dr Simon Lord, Consultant Medical Oncologist, University of Oxford.



Prof Gareth Bond. Genetics and Genomics University of Birmingham




Prof Xin Lu Ludwig Institute University of Oxford



Radiology Lead

Dr Jamie Franklin **Consultant Radiologist** Bournemouth University



Principal Investigator Oxford

Dr Lara Hawkes **Consultant Cancer** Geneticist, University of Oxford. BRCA risk stratification

Principal Investigator Manchester

Dr Emma Woodward **Consultant Cancer** Geneticist, University of Manchester.

Principal Investigator London

Dr Angela George **Consultant Cancer** Geneticist, Royal Marsden Hospital, London

Principal Investigator

Cambridge

Prof Marc Tischkowitz **Consultant Cancer** Geneticist, University of Cambridge

Statistician

Prof John Norrie Statistics, University of Edinburgh

Coordinating Principal Investigator



Dr Helen Hanson **Consultant Cancer** Geneticist, St Georges Hospital, London

Sponsor:



Funders:





Integrated PPI representatives









Verity Easton





and related conditions



- Does metformin prevent or delay the emergence of cancer in people with LFS provide evidence for licencing decision
- Why does cancer happen in LFS? insights into tumorigenesis from serial blood sampling, measurement of mitochondrial activity etc.
- Are some P53 mutations more cancer-forming than others? sequencing correlation with outcome to provide prognostic information
- What is the impact of yearly prevention and/or surveillance on quality of life? QOL data (fear of cancer scale)




- 224 people aged ≥16y with LFS in UK, recruitment commences January 2023
- Randomised 1:1 to cancer surveillance and metformin versus cancer surveillance alone
- Precision-Prevention Design
- Those randomised to metformin will receive it by post, have telephone side effect assessment
- Surveillance will comprise annual whole body and brain MRI and dermatological examination
- Four centres: Oxford, London (RMH), Cambridge and Manchester will act as Trial Centres for consenting and scanning with regional genetics units acting as research sites
- Recruit over 2 years and on metformin for 5 years
- Data pooled into a single international meta-analysis.



How are participants identified?



Dr Helen Hanson





Eligible if:

- Confirmed pathogenic form of LFS
- Aged 16 or over
- Not currently taking metformin
- No current cancer or having chemotherapy (for last 6 months)
- Not pregnant
- No serious heart, kidney or liver problems
- Not diabetic
- Can tolerate MRI (ie no pacemaker etc)



What happens then?



Referred to nearest of four Major Genetics Centres To consent and undergo blood tests and MRI

Blood tests: full blood count, liver and kidney tests (eGFR), pregnancy test

MRI: Whole body (and brain)

Detailed questionnaire: family history, diet etc.










The Randomisation Process





Updates by phone from Oxford-based study nursing team




Metformin arm of the study



6 month's supply of metformin delivered by post

One in the morning for 2 weeks








One in morning, one in evening for 2 weeks







Two in morning, one in evening for 2 weeks












MILI EVENTS





- Does metformin prevent or delay the emergence of cancer in people with LFS provide evidence for licencing decision
- Why does cancer happen in LFS? insights into tumorigenesis from serial blood sampling, measurement of mitochondrial activity etc.
- Are some P53 mutations more cancer-forming than others? sequencing correlation with outcome to provide prognostic information
- What is the impact of yearly prevention and/or surveillance on quality of life? QOL data (fear of cancer scale)



What questions is MILI asking?


- Does metformin prevent or delay the emergence of cancer in people with LFS provide evidence for licencing decision
- Why does cancer happen in LFS? insights into tumorigenesis from serial blood sampling, measurement of mitochondrial activity etc.
- Are some P53 mutations more cancer-forming than others? sequencing correlation with outcome to provide prognostic information
- What is the impact of yearly prevention and/or surveillance on quality of life? QOL data (fear of cancer scale)



How does metformin work – direct or indirect?




Direct





Measure by genetic signature from blood


Indirect






How does metformin work – direct or indirect?







P53 mutations and cancer



Are certain P53 mutations linked to certain cancers?

Are there markers in the blood that can be used to track the emergence of cancer?

Can vaccines be developed against them?



Quality of Life

- Yearly Quality of Life Questionnaires similar to those used in SIGNIFY study SF12v2, Cancer Worry Scale, Impact of Events scale
 - SF12 (short form) 12 questions quick overview of general health, energy and stress levels
 - Your feelings about screening and its impact on your mood & thoughts
 - How LFS bothers you on a day to day basis (past 7 days)
- Metformin compliance questionnaire (metformin arm)








Educating next generation of radiologists






MRI images collected in large anonymised database to teach radiologists






- Largest study of its type in LFS X
- Designed with close involvement from LFS community
- One of the first Precision Prevention trials
- Will tell us if metformin delays/reduces risk of cancer (endpoints may extend) so that metformin could be licenced
- Will use a Translational Data Platform to tell us how metformin works
- Will collect blood to test biomarkers that may predict cancer early
- Will provide coordinated MRI for people with LFS around the UK
- Will tell us whether certain mutations are more cancer-prone than other (riskadjusted screening)
- Will validate SIGNIFY's quality of life findings (about the benefits of MRI) in a larger patient group
- Will provide a database to teach WB+B MRI reporting
- Will seed future prevention studies (e.g. using vaccines)



Thank you! **Recruitment starts January 2023**







Elizabeth Sam

Verity Easton

TP53 Trust





CANCER RESEARCH



19









Are you a BRCA mutation carrier? Do you have Lynch or Li Fraumeni Syndromes?

Join us to share your ideas about the type of research into new treatments to prevent or delay cancer you would like us to explore



Wed 21st Sept 22 | 4pm-6pm | Virtual Meeting **Register and find out more:** <u>www.cancer.ox.ac.uk/ppm</u>